12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Melapuldencel-T: SPA received

California Stem Cell received an SPA from FDA for a double-blind, U.S. Phase III trial to compare subcutaneous DC-TC vs. peripheral blood mononuclear cells (PBMCs) in about 250 patients with recurrent stage III or IV...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >